PBT turned positive at NZD 0.9m but a NZD 3.4m tax charge swamped the bottom...

What changed

The prior comparable period (HY22) included a discontinued ANZ operation, so headline comparisons are not clean like-for-like. With that caveat, FY23 continuing-operations revenue came in at NZD 56.1m versus NZD 4.6m for the prior half-year period — a structural shift rather than an organic growth read. The more useful internal comparison is that FY23 revenue was 17.9% higher than the equivalent prior full-year continuing operations figure, per the NZX form.

• Gross margin compressed by approximately 495 basis points to 32.4% as cost of sales rose faster than revenue, narrowing gross profit to NZD 18.2m from NZD 17.8m despite substantially higher turnover.
• Operating profit turned positive at NZD 2.2m (prior: NZD -1.3m), and PBT moved to NZD 0.9m from NZD -0.9m — the cleanest measure of operating progress.
• NPAT was NZD -2.5m against NZD 0.1m in the prior period, but the swing is entirely explained by a NZD 3.4m tax charge against PBT of NZD 0.9m, producing an effective tax rate of approximately 378%. The prior period carried a NZD 0.6m contribution from the discontinued ANZ operation; that income is now absent.
• Operating cash flow improved materially to NZD 6.5m from NZD 0.1m, with virtually all of the NZD 8.9m second-half operating cash inflow driving the improvement (the first half recorded an outflow of NZD 2.4m).
• Net debt fell sharply to NZD 13.0m from NZD 29.9m, supported by inventory drawdown of NZD 9.8m and the cash accumulation to NZD 12.7m.

What matters

1. The tax charge is the central distortion, and its durability is unclear. PBT of NZD 0.9m becoming an NPAT loss of NZD 2.5m reflects an effective tax rate of ~378%. No reconciliation of deferred tax movements or unrecognised tax losses was provided in the excerpts. Until the composition of that NZD 3.4m charge is disclosed — whether it is a one-time deferred tax adjustment, a write-down of deferred tax assets, or a structural feature of the multi-currency US/Brazil/NZ structure — the NPAT line cannot be treated as indicative of ongoing earnings capacity.

2. Gross margin compression warrants attention. Despite revenue growth, gross margin fell ~495 bps to 32.4%. In a business whose stated strategy is to grow sales of higher-margin proprietary advanced genetic products (MCP), margin compression in the wrong direction is a signal worth tracking. The excerpts do not disaggregate product mix, so it is unclear whether this reflects pricing, input costs, or a shift toward lower-margin volume.

3. Balance-sheet deleveraging is a genuine positive. Gross borrowings fell NZD 8.1m to NZD 25.7m, and net debt halved to NZD 13.0m. Inventory reduction of NZD 9.8m drove much of the cash improvement. This strengthens the company's stated goal of greater financial flexibility post the ANZ disposal.

Expectations

No quantified FY24 guidance or formal earnings target was disclosed in the supplied material. The prior period's interim release referenced a US GAAP EBITDA range of USD 11.3–11.7m for FY22, but no equivalent target exists in the current release excerpts, so a run-rate comparison against stated targets cannot be made.

The half-year shape is informative: HY23 contributed only 13.2% of full-year revenue (NZD 7.4m versus NZD 56.1m), reflecting the well-established seasonal pattern of seedling delivery concentrated in the second half (spring planting season). First-half losses are structurally normal for this business; the NZD 1.6m HY23 NPAT loss representing 64% of the full-year loss implies the second half narrowed losses to NZD 0.9m, consistent with a business that earns its operating income almost entirely in H2.

The 17.9% revenue growth cited in the NZX form, if sustained, would represent continued execution on the MCP volume growth thesis. Whether MCP mix within that revenue grew or declined is not determinable from the disclosed figures.

Quality of result

The operating cash flow improvement is the most durable element of FY23. Cash conversion from operating activities was strong in H2 and the reduction in inventory — from NZD 41.4m to NZD 31.6m, with inventory days improving from ~507 to ~304 — reflects genuine working capital discipline rather than accounting presentation.

Free cash flow after capex was only NZD 0.9m, however, because capex stepped up significantly to NZD 5.6m (from NZD 1.9m), split NZD 2.2m in fixed assets and NZD 3.4m in intellectual property. The IP capex is consistent with investment in genetic material and breeding programmes, which is core to the strategy but inherently long-cycle.

The PBT improvement to NZD 0.9m is real but slim, and the gross margin contraction introduces doubt about whether the quality of revenue growth matches the quantity. The NZD 3.4m tax charge is an adverse timing or structural item that overstates the economic loss for FY23 on the surface; conversely, if deferred tax assets are being partially written off, that is a negative signal about earnings visibility.

No dividend was proposed, which is consistent with the loss position and the ongoing investment phase.

Unresolved

• The composition of the NZD 3.4m tax charge at an effective rate of ~378% is not explained in the excerpts. Is this a deferred tax asset write-down, a multi-jurisdictional timing difference, or a structural cost of the US/Brazil/NZ structure?
• Gross margin fell ~495 bps despite a strategy premised on higher-margin MCP product growth. The filing does not disclose whether MCP volume or revenue mix actually increased as a share of total sales in FY23.
• The FX relationship between USD-denominated operations and the NZD reporting currency is material but unquantified. No hedge position or sensitivity range was disclosed.
• Inventory remains elevated at NZD 31.6m (representing ~304 days of cost of sales). The pace and circumstances of further drawdown — whether demand-driven or managed — are not clear.
• No FY24 guidance, forward order book, or volume targets were disclosed, leaving the revenue trajectory unsupported by any company-provided anchor.

This briefing cannot assess whether the NZD 3.4m tax charge is a recurring structural cost or a one-time adjustment, which is the single most important input for estimating normalised earnings power.

Key metrics

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.